TAKAYASU ARTERITIS
Clinical trials for TAKAYASU ARTERITIS explained in plain language.
Never miss a new study
Get alerted when new TAKAYASU ARTERITIS trials appear
Sign up with your email to follow new studies for TAKAYASU ARTERITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to tame rare artery disease
Disease control Not yet recruitingThis phase 2 trial tests whether secukinumab, a drug that blocks IL-17A, can help people with active severe Takayasu arteritis achieve remission and stop taking steroids. About 52 participants will receive either secukinumab injections or standard care (like TNF inhibitors). The …
Matched conditions: TAKAYASU ARTERITIS
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
Could a lung drug fix blood vessel damage in rare artery disease?
Disease control Not yet recruitingThis study tests whether adding pirfenidone, a drug used for lung and liver scarring, to standard treatment can improve blood vessel damage in people with Takayasu arteritis. About 92 adults aged 18-60 will receive either pirfenidone or a placebo for 6 months. The goal is to see …
Matched conditions: TAKAYASU ARTERITIS
Phase: PHASE4 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC
-
New scanner aims to sharpen diagnosis of blood vessel disease
Diagnosis Not yet recruitingThis study will test a new type of PET/CT scanner (called long-axial field-of-view) to see if it can provide clearer images of inflammation in the blood vessels of people with large vessel vasculitis. Researchers will compare scans from 18 participants (12 with vasculitis and 6 h…
Matched conditions: TAKAYASU ARTERITIS
Phase: NA • Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jun 22, 2026 11:59 UTC